Default company panoramic image
Logo

Med3 Dermaceuticals

Healing Diabetic and Pressure Sore wounds where no one has healed before!

  • Stage Product In Development
  • Industry Biotechnology
  • Location Los Altos, CA, USA
  • Currency USD
  • Founded October 2007
  • Employees 5
  • Website med3derm.com

Company Summary

Med3 Dermaceuticals has operated in the capacity of a skin care company, but has developed a formulation which has the potential to heal diabetic and pressure sore (bed sores) wounds. The company has done preliminary studies at the Tokyo Adventist Hospital showing significant wound healing in diabetic patients. The company is currently looking for funding to get animal testing done to progress through the FDA 510 registration process.

Team

  • Default avatar
    Barbara Elisabeth Morrison
    President - CEO

    Barbara Morrison is the President and is responsible for the product placement, distribution, and marketing materials. Barbara Morrison has Business degree from the University of Nevada-Reno. Ms. Morrison has been an entrepreneur for 16 years in the resort area of Lake Tahoe. She also has experience working with the Hyatt in their elegant Stillwater Spas.

  • Default avatar
    H. Michael Schneider
    Investor

    Mr. Schneider is a long time business owner on the Bay Area Peninsula who's business, Romic Environmental Services was the largest independent chemical recycling company in the country. Romic was sold in 1999 for $32 million. At the time, Mr. Schneider had 5 locations and over 300 employees. Since that time, Mr. Schneider has been involved in health related companies. Mr. Schneider funded the original collagen research that Med3 is based on.

  • Default avatar
    Roberto Narimatsu
    Lead Researcher

    Roberto Narimatsu is the lead Doctor in charge of Research and Development.
    He worked at Northwestern in Chicago studying viruses, AIDS in particular. He was then transferred to Stanford where he continued his research. He has several papers published at both institutions. Due to funding issues, he was available to work with Med3 and beginning research with proteins. He now works with proteins and creates formulations for Med3. Find some

Advisors

  • Default avatar
    Heffernan Seubert & French LLP
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    H. Michael Schneider
    Unconfirmed
    Default avatar
    Barbara E. Morrison
    Unconfirmed